AIMS: Chronic heart failure (CHF) causes inspiratory (diaphragm) muscle weakness and fatigue that contributes to dyspnoea and limited physical capacity in patients. However, the mechanisms that lead to diaphragm dysfunction in CHF remain poorly understood. Cytokines and angiotensin II are elevated in CHF and stimulate the activity of the enzyme sphingomyelinase (SMase) and accumulation of its reaction product ceramide. In the diaphragm, SMase or ceramide exposure in vitro causes weakness and fatigue. Thus, elevated SMase activity and ceramide content have been proposed as mediators of diaphragm dysfunction in CHF. In the present study, we tested the hypotheses that diaphragm dysfunction was accompanied by increases in diaphragm SMase activity and ceramide content. METHODS AND RESULTS: Myocardial infarction was used to induce CHF in rats. We measured diaphragm isometric force, SMase activity by high-performance liquid chromatography, and ceramide subspecies and total ceramide using mass spectrometry. Diaphragm force was depressed and fatigue accelerated by CHF. Diaphragm neutral SMase activity was increased by 20% in CHF, while acid SMase activity was unchanged. We also found that CHF increased the content of C18 -, C20 -, and C24 -ceramide subspecies and total ceramide. Downstream of ceramide degradation, diaphragm sphingosine was unchanged, and sphingosine-1-phosphate level was increased in CHF. CONCLUSION: Our major novel finding was that diaphragm dysfunction in CHF rats was accompanied by higher diaphragm neutral SMase activity, which is expected to cause the observed increase in diaphragm ceramide content.
AIMS: Chronic heart failure (CHF) causes inspiratory (diaphragm) muscle weakness and fatigue that contributes to dyspnoea and limited physical capacity in patients. However, the mechanisms that lead to diaphragm dysfunction in CHF remain poorly understood. Cytokines and angiotensin II are elevated in CHF and stimulate the activity of the enzyme sphingomyelinase (SMase) and accumulation of its reaction product ceramide. In the diaphragm, SMase or ceramide exposure in vitro causes weakness and fatigue. Thus, elevated SMase activity and ceramide content have been proposed as mediators of diaphragm dysfunction in CHF. In the present study, we tested the hypotheses that diaphragm dysfunction was accompanied by increases in diaphragm SMase activity and ceramide content. METHODS AND RESULTS:Myocardial infarction was used to induce CHF in rats. We measured diaphragm isometric force, SMase activity by high-performance liquid chromatography, and ceramide subspecies and total ceramide using mass spectrometry. Diaphragm force was depressed and fatigue accelerated by CHF. Diaphragm neutral SMase activity was increased by 20% in CHF, while acid SMase activity was unchanged. We also found that CHF increased the content of C18 -, C20 -, and C24 -ceramide subspecies and total ceramide. Downstream of ceramide degradation, diaphragm sphingosine was unchanged, and sphingosine-1-phosphate level was increased in CHF. CONCLUSION: Our major novel finding was that diaphragm dysfunction in CHFrats was accompanied by higher diaphragm neutral SMase activity, which is expected to cause the observed increase in diaphragm ceramide content.
Authors: Wilhelm Stoffel; Britta Jenke; Barbara Blöck; Markus Zumbansen; Jürgen Koebke Journal: Proc Natl Acad Sci U S A Date: 2005-03-11 Impact factor: 11.205
Authors: Wolfram Doehner; Alexander C Bunck; Mathias Rauchhaus; Stephan von Haehling; Frank M Brunkhorst; Mariantonietta Cicoira; Carsten Tschope; Piotr Ponikowski; Ralf A Claus; Stefan D Anker Journal: Eur Heart J Date: 2007-03-12 Impact factor: 29.983
Authors: Stephan Gielen; Volker Adams; Axel Linke; Sandra Erbs; Sven Möbius-Winkler; Andreas Schubert; Gerhard Schuler; Rainer Hambrecht Journal: Eur J Cardiovasc Prev Rehabil Date: 2005-08
Authors: Pedro Dall'Ago; Gaspar R S Chiappa; Henrique Guths; Ricardo Stein; Jorge P Ribeiro Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Hieronymus W H van Hees; Henricus F M van der Heijden; Theo Hafmans; Leo Ennen; Leo M A Heunks; Freek W A Verheugt; P N Richard Dekhuijzen Journal: Int J Cardiol Date: 2007-08-08 Impact factor: 4.164
Authors: Hieronymus W H van Hees; Henricus F M van der Heijden; Coen A C Ottenheijm; Leo M A Heunks; Cindy J C Pigmans; Freek W A Verheugt; Rene M H J Brouwer; P N Richard Dekhuijzen Journal: Am J Physiol Heart Circ Physiol Date: 2007-04-20 Impact factor: 4.733
Authors: Norman Mangner; Axel Linke; Andreas Oberbach; Yvonne Kullnick; Stephan Gielen; Marcus Sandri; Robert Hoellriegel; Yasuharu Matsumoto; Gerhard Schuler; Volker Adams Journal: PLoS One Date: 2013-01-02 Impact factor: 3.240
Authors: T Scott Bowen; Norman Mangner; Sarah Werner; Stefanie Glaser; Yvonne Kullnick; Andrea Schrepper; Torsten Doenst; Andreas Oberbach; Axel Linke; Leif Steil; Gerhard Schuler; Volker Adams Journal: J Appl Physiol (1985) Date: 2014-10-30
Authors: Bumsoo Ahn; Adam W Beharry; Gregory S Frye; Andrew R Judge; Leonardo F Ferreira Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-07-24 Impact factor: 5.464
Authors: Philip D Coblentz; Bumsoo Ahn; Linda F Hayward; Jeung-Ki Yoo; Demetra D Christou; Leonardo F Ferreira Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-01-31 Impact factor: 5.464